AstraZeneca's Imfinzi immunotherapy drug extended early-stage small cell lung cancer survival by two years in a trial, reducing death risk by 27%.
AstraZeneca's Imfinzi, an immunotherapy drug, has shown in a new clinical trial to extend survival by two years in early stages of small cell lung cancer, with a 27% reduced risk of death compared to a placebo. The trial, Adriatic, used Imfinzi as a consolidation therapy following initial chemotherapy and radiation for patients with limited stage disease. The drug's sales reached $4.2 billion last year, and AstraZeneca aims to target $80 billion in annual sales by 2030.
June 02, 2024
3 Articles